Killing two birds with one stone, Gilead Sciences Inc. has granted non-exclusive licenses for remdesivir to Mylan NV, Cipla Ltd., Jubilant Life Sciences Ltd., Hetero Drugs Ltd. and Ferozsons Laboratories Ltd. for 127 developing countries, including several from Asia but excluding China, thus tilting the pricing debate in its favor while creating substantial capacity for its production.
The investigational drug is currently at the forefront of the fight against COVID-19, with the US having granted Emergency Use Authorization (EUA) and drug regulatory authorities in Japan on 7 May joining in with an